Close Menu

Enzo

After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.

The firm said the decline in Q4 revenues was due to an account loss as well as lower insurance reimbursement and shifts away from high-value genetic testing.

A brief recap of Genetics/Genomics news the week of Aug 31, 2018: Perosnalize Medicine Coalition, Enzo Biochem, Hoosier Cancer Research Network, Scor Global Life, and ALCF

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

The firm said that the decline was due to a customer shifting to internalizing genetic ordering, adverse weather, and the loss of an undisclosed commercial payor.  

The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.

The firm said the increase in overall revenues was due largely to a 4 percent increase in clinical labs revenues, while product revenues inched up 1 percent year over year.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

The company said the revenue growth was largely due to double-digit growth in its clinical labs business.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.